Core Viewpoint - Haili Biological announced that its subsidiary, Ruisheng Biological, has had its Class III medical device "Natural Bone Repair Material" registration application accepted by the National Medical Products Administration, which is expected to enhance its product line in the oral bone defect repair sector [1] Group 1 - The product is designed for maxillary bone defect repair and utilizes a more efficient production process, leading to faster and more stable bone repair outcomes [1] - Approval of the product for market launch will diversify Ruisheng Biological's offerings in the oral bone defect repair field [1]

Group 1 - Dematech won a 900 million yuan overseas smart logistics project from a well-known e-commerce giant in Latin America, focusing on intelligent logistics cross-belt sorting systems and related services [1] - Kang En Bei received approval for the registration of short-term financing bonds and medium-term notes, with a total registration amount of 1 billion yuan, valid for two years [1][2] - Zhi Xiang Jin Tai's GR1803 injection for systemic lupus erythematosus clinical trial has been approved by the National Medical Products Administration [2] Group 2 - Jin Da Wei's subsidiary received approval for a veterinary drug product, pyridone, valid from September 3, 2025, to September 2, 2030 [4] - Fu Li Wang's subsidiary plans to invest 500 million yuan in a high-end wire material project, focusing on high-strength prestressed steel strands for various applications [5] - He Li Biological's subsidiary's Class III medical device registration application has been accepted, focusing on natural bone repair materials [12] Group 3 - Lin Yang Energy won a 244 million yuan metering equipment project from Southern Power Grid, expected to positively impact its 2025 and 2026 performance [20] - Sanxia Water plans to absorb its wholly-owned subsidiary, Chongqing Changdian United Energy, with all assets and liabilities to be inherited by Sanxia Water [13] - Tian Cheng Technology canceled the use of 91 million yuan of raised funds for permanent working capital, ensuring no impact on the normal operation of investment projects [24] Group 4 - Baosteel received approval to publicly issue bonds totaling 20 billion yuan to professional investors, valid for 24 months [52] - Tian Kang Biological reported a 10.15% year-on-year increase in pig sales in August, with a total of 263,800 pigs sold [53] - Xinjiang Construction won multiple major projects totaling 4.506 billion yuan, including a 2.4 billion yuan photovoltaic hydrogen synthesis project [18]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 证券代码：603718 证券简称：海利生物 公告编号：2025－039 上海海利生物技术股份有限公司 关于控股子公司三类医疗器械注册申请获得受理的公告 上海海利生物技术股份有限公司（以下简称"公司"）控股子公司陕西瑞盛生物 科技有限公司（以下简称"瑞盛生物"）于近日收到国家药品监督管理局（以下简称 "国家药监局"）下发的医疗器械注册申请受理通知信息，现将相关情况公告如下： 一、该医疗器械的基本信息 申请人：陕西瑞盛生物科技有限公司 产品名称：天然骨修复材料 受理号：CQZ2501670 产品类别：第三类医疗器械 二、 目前所处审批阶段 该医疗器械目前注册申请已获得受理。 三、 后续所需审批流程 后续所需的审批流程：审评审批、制证。 临床用途：适用于颌骨缺损修复 异种骨修复材料因其形态和多孔结构与天然骨相似，有利于骨细胞长入及骨组织 分化形成。通过物理化学方法可去除其免疫原性，具备来源广泛、制造成本低、获取 与加工便捷、生物力学性能优良、能被机体吸收降解等优势，在口腔骨修复市 ...

Market Overview - The animal health sector experienced a decline of 0.5% on September 10, with Yongshun Biological leading the drop [1] - The Shanghai Composite Index closed at 3812.22, up 0.13%, while the Shenzhen Component Index closed at 12557.68, up 0.38% [1] Stock Performance - Notable gainers included: - Qudongli (838275) with a closing price of 11.21, up 2.75% [1] - *ST Lvkang (002868) at 26.42, up 1.62% [1] - Houfeng Holdings (002141) at 4.00, up 0.76% [1] - Major decliners included: - Yongshun Biological (839729) at 10.62, down 3.28% [2] - Shilian Biological (688098) at 11.72, down 1.76% [2] - Huai Sheng Biological (300871) at 22.20, down 1.60% [2] Capital Flow Analysis - The animal health sector saw a net outflow of 81.6 million yuan from institutional investors, while retail investors contributed a net inflow of 53.0 million yuan [2] - The detailed capital flow for key stocks showed: - Repu Biological (300119) had a net inflow of 1.12 million yuan from retail investors [3] - Kexian Biological (688526) saw a net inflow of 14.78 thousand yuan from institutional investors [3] - Hai Li Biological (603718) experienced a significant net outflow of 22.66 million yuan from institutional investors [3]

Core Viewpoint - Haili Biological (603718.SH) announced that its subsidiary, Shaanxi Ruisheng Biological Technology Co., Ltd., received a medical device registration application acceptance notice from the National Medical Products Administration for a natural bone repair material [1] Company Summary - The product is classified as a Class III medical device under the Medical Device Classification Rules and falls under the category of oral medical devices, specifically for bone filling and repair materials [1] - The product classification code is 17-08-06, indicating its specific use in oral cavity bone defect repair [1] - Once approved, this product will enhance Ruisheng Biological's product line in the field of oral bone defect repair [1]

海利生物公告，控股子公司陕西瑞盛生物科技有限公司于近日收到国家药品监督管理局下发的医疗器械 注册申请受理通知。该医疗器械为天然骨修复材料，适用于颌骨缺损修复。受理号为CQZ2501670，产 品类别为第三类医疗器械。目前注册申请已获得受理，后续需经过审评审批、制证等流程。该产品为Ⅲ 类医疗器械，获批上市后将在口腔骨缺损修复领域丰富瑞盛生物的产品线。 ...

Market Overview - The animal health sector increased by 1.25% on September 5, with Yongshun Biological leading the gains [1] - The Shanghai Composite Index closed at 3812.51, up 1.24%, while the Shenzhen Component Index closed at 12590.56, up 3.89% [1] Stock Performance - Yongshun Biological (839729) closed at 10.82, up 4.14% with a trading volume of 44,500 shares and a turnover of 47.80 million yuan [1] - Shilian Biological (688098) closed at 11.76, up 3.16% with a trading volume of 114,100 shares and a turnover of 132 million yuan [1] - Other notable performers include: - Houfeng Holdings (002141): closed at 3.96, up 2.33% [1] - KQ Biological (688526): closed at 18.00, up 2.16% [1] - Dayu Biological (871970): closed at 10.25, up 2.09% [1] Capital Flow - The animal health sector experienced a net outflow of 37.19 million yuan from institutional investors, while retail investors saw a net inflow of 13.24 million yuan [2] - Notable capital flows include: - Shilian Biological: net inflow of 500.11 thousand yuan from institutional investors [3] - Houfeng Holdings: net inflow of 91.15 thousand yuan from retail investors [3] - KQ Biological: net outflow of 297.54 thousand yuan from institutional investors [3]

Market Overview - The animal health sector experienced a decline of 0.2% on September 4, with Shunlian Biological leading the drop [1] - The Shanghai Composite Index closed at 3765.88, down 1.25%, while the Shenzhen Component Index closed at 12118.7, down 2.83% [1] Stock Performance - Notable gainers in the animal health sector included: - Qudongli (code: 838275) with a closing price of 11.96, up 6.50% [1] - Dayu Biological (code: 871970) with a closing price of 10.04, up 3.40% [1] - Yongshun Biological (code: 839729) with a closing price of 10.39, up 2.26% [1] - Conversely, Shunlian Biological (code: 688098) saw a decline of 2.98%, closing at 11.40 [2] Trading Volume and Capital Flow - The total trading volume for the animal health sector showed a net outflow of 85.41 million yuan from institutional investors, while retail investors saw a net inflow of 74.17 million yuan [2] - The capital flow for individual stocks indicated significant movements, with Shunlian Biological experiencing a net outflow of 10.12 million yuan from institutional investors [3] Individual Stock Analysis - Shunlian Biological had a total trading volume of 131,200 shares, with a net inflow of 7.73 million yuan from retail investors [3] - Other stocks like Huisheng Biological (code: 300871) and ST Green Kang (code: 002868) also showed varied capital flows, with Huisheng experiencing a net outflow of 12.50 million yuan from speculative funds [3]

Market Overview - The animal health sector experienced a decline of 2.2% on September 3, with the leading stock, Driveline, falling by 8.33% [1] - The Shanghai Composite Index closed at 3813.56, down 1.16%, while the Shenzhen Component Index closed at 12472.0, down 0.65% [1] Stock Performance - Key stocks in the animal health sector showed significant declines, with Driveline (code: 838275) closing at 11.23, down 8.33% on a trading volume of 49,500 shares and a transaction value of 57.66 million yuan [1] - Other notable declines included: - Yongshun Biological (code: 839729) down 4.78% to 10.16 [1] - Jinhai Biological (code: 002688) down 4.03% to 6.91 [1] - ST Lvkang (code: 002868) down 3.30% to 26.35 [1] - Houbang Holdings (code: 002141) down 3.24% to 3.88 [1] Capital Flow - The animal health sector saw a net outflow of 108 million yuan from major funds, while retail investors contributed a net inflow of 101 million yuan [1] - Detailed capital flow for specific stocks indicated: - Shunlian Biological (code: 688098) had a net inflow of 8.21 million yuan from major funds [2] - ST Lvkang (code: 002868) experienced a net outflow of 2.26 million yuan from major funds [2] - Houbang Holdings (code: 002141) faced a significant net outflow of 24.59 million yuan from major funds [2]

Core Viewpoint - Shanghai Haili Biological Technology Co., Ltd. announced that its subsidiary, Shaanxi Ruisheng Biotechnology Co., Ltd., has received a notice of acceptance from the National Medical Products Administration for the registration application of three types of medical devices, specifically "bone repair materials" [1] Group 1: Product Details - The products are classified as Class III medical devices, suitable for filling and repairing maxillofacial bone defects and alveolar bone defects (or insufficient bone volume) [1] - The application includes structured products such as block and column types, which can better match the bone defect areas compared to the existing granular bone repair materials, effectively reducing bone powder displacement and improving surgical efficiency and osteogenic effects [1] Group 2: Regulatory Process - The registration application is currently in the review and approval stage, with a statutory administrative approval period of 20 working days, which can be extended by an additional 10 working days under special circumstances [1] Group 3: Market Implications - If the product is successfully approved for market launch, it will enrich Haili Biological's product line in the field of oral bone defect repair [1] - The company notes that the product is still in the acceptance stage, and its impact on future performance remains uncertain [1]